About this company
Ymmunobio has identified a new tumor marker with superior properties: 1. It is present in at least 13 solid tumors 2. It has a prevalence of up to 98% in cancer patients 3. It is not expressed by normal tissue Ymmunobio has built a complete development program around this novel target featuring three therapeutic antibodies: 1. YB-800ADC, an ADC with linkers of the 3rd generation 2. YB-800R1&2, 2 radio pharmaceuticals in collaboration with the Paul Scherrer Institut (PSI) supported by an Innosuisse grant 3. YB-800BS1&2, 2 bi-specific antibody with an aCD3 T-cell engager In addition, Ymmunobio is also developing two companion diagnostics, one for SPECT imaging (with PSI) and one blood test for cancer screening and patient eligibility (with EVIIVE)